A Study to Assess the Bioequivalence of a New ULTRACET Extended Release (ER) Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Condition

NCT01778075 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)
DRUG: Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)

Sponsor

Janssen Korea, Ltd., Korea